Patients Stopping Slimming Jabs Regain Weight at a Quadrupled Rate Than Dieters

Fresh analysis reveals that people who stop using blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional diet and exercise plans.

Research printed in a major medical journal demonstrates that while obese people often shed about a fifth of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month after stopping.

"Individuals purchasing these medications must be informed of the danger of rapid weight regain when the therapy concludes," stated researcher Dr. Susan Jebb.

This pace of recovery implies a return to original mass within about one and a half years.

Weighing Approaches

The analysis, which looked at dozens of studies involving thousands of participants, compared the effects of the injectable medications with other pills.

Scientists emphasize that individuals who lose weight through diet and exercise typically see a more gradual creep back—approximately 100 grams monthly—after stopping.

Understanding the Rapid Regain

Nutrition scientists propose the way of the injections is key to understanding the accelerated rebound.

The injections imitate a natural hormone called glucagon-like peptide-1, which moderates hunger.

"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making excessive eating much more probable."

A Chronic Issue?

Health authorities suggest the injections for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.

Many experts say that, considering the significant potential of weight regain, the therapy is often life-long.

This perspective is reinforced by pharmaceutical companies, who state that the results "underscore the long-term character of obesity," akin to managing diseases like diabetes.

Patient Accounts

People who have discontinued the medication describe a sudden resurgence of cravings.

"I experienced a switch that goes on and I was suddenly starving," recalled one woman.

This challenge is compounded if users have not established permanent lifestyle or habit changes during therapy.

Widespread Use

Recent estimates show that millions of adults in the UK have used weight-loss jabs in the last 12 months, with demand being substantial.

• Adoption is more common among women compared to men.
• The middle-aged demographic shows the highest level of interest.
• A large proportion obtain the drugs through private healthcare rather than public health services.

In conclusion, researchers emphasize that while the jabs are potent tools for weight loss, they are not a standalone cure and lasting health benefits relies on ongoing behavioural support.